A malaria vaccine developed by University of Oxford and Serum Institute of India, leveraging Novavax’s adjuvant, has been recommended for use by WHO. The R21/Matrix-M vaccine is cost-effective and easily deployable, with production capacity already established for 100 million doses per annum.